ReviewCurrent cardiology reports2026
Feasibility of Quantitative Myocardial Perfusion with CZT SPECT and SPECT/CT: Current Limitations and Recommendations for Future Improvements.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations of AI-derived coronary CT angiography features with CZT-SPECT coronary flow reserve and FFR-CT.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMeasurement of absolute myocardial blood flow (MBF) improves on relative myocardial perfusion imaging (MPI). It can more accurately identify multi-vessel disease and aid in the assessment of microvascular disease. It also provides independent prognostic information for risk stratification. The advent of solid-state stationary SPECT systems has led to renewed interest in the use of SPECT to measure absolute myocardial blood flow. The large utilization of SPECT for MPI means that there is a large potential impact from the clinical implementation of SPECT MBF. In this paper we review the evidence validating SPECT MBF measurements and discuss its limitations and some directions for development that could further improve its performance. RECENT
findingsSPECT MBF correlates well with angiographic measurements of coronary artery disease and with MBF values from PET imaging. A current limitation is its repeatability which might be improved by new tracers with increased extraction fraction, more advanced reconstruction algorithms, and increased automation in analysis software. Study duration could be reduced through careful application of rapid acquisition protocols, and larger studies are needed to demonstrate potential benefit of SPECT MBF measurements. SPECT MBF is a promising technology that is feasible to use clinically. Several research directions are possible to enhance precision and reduce the time needed for study acquisition and processing.
Indexed as
Identifiers
41876902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.